Literature DB >> 2204660

Major histocompatibility complex antigens in human liver transplants.

G Steinhoff1.   

Abstract

Liver transplantation is performed successfully across major HLA differences between donor and recipient. This may be influenced by the organ specific expression of major histocompatibility complex (MHC) molecules which determine the local immune reactivity and rejection response. The tissue expression of MHC molecules on parenchymal and infiltrating cells has been studied in transplanted human liver using monoclonal antibodies and immunohistological methods. A strong induction of class I (HLA-A,B,C; beta 2-microglobulin) and class II (HLA-DR,DQ,DP) MHC antigens was demonstrated on hepatocytes, bile duct epithelium and endothelial cells during rejection episodes and viral and bacterial infections. The massive induction of donor antigens on hepatocytes, bile ducts and endothelia forms part of, and may also augment, the rejection response. During quiescent states without infection or rejection after transplantation, however, a rather restricted expression of class I and class II donor MHC antigens is present. In addition, the donor Kupffer cells and interstitial dendritic cells are gradually replaced by recipient accessory cells expressing self-MHC molecules. The changes in antigen density and distribution of donor MHC alloantigens as the replacement of accessory cells capable of presenting antigens to T-lymphocytes may influence the course of immune reactivity and the rejection response in the liver. This may partly explain the favourable clinical course long after transplantation. Preliminary clinical investigations of the effect of HLA matching have shown a dualistic effect of the matching of class I or class II HLA antigens. The role of HLA matching in liver transplants in large clinical studies, with specific immunological testing however, remains to be investigated. This may lead to prospective HLA matching with wider organ availability and improved preservation time in the future.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204660     DOI: 10.1016/0168-8278(90)90264-r

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

Review 1.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

Review 2.  HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition.

Authors:  Michael Campoli; Soldano Ferrone
Journal:  Semin Immunopathol       Date:  2011-04-28       Impact factor: 9.623

3.  The role of graft-resident Kupffer cells and lymphocytes of donor type during the time course after liver transplantation--a clinico-pathological study.

Authors:  Iris Bittmann; Adriana Bottino; Gustavo Bruno Baretton; Alexander Ludwig Gerbes; Reinhart Zachoval; Horst Günter Rau; Udo Löhrs
Journal:  Virchows Arch       Date:  2003-07-23       Impact factor: 4.064

4.  De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.

Authors:  H Kaneku; J G O'Leary; N Banuelos; L W Jennings; B M Susskind; G B Klintmalm; P I Terasaki
Journal:  Am J Transplant       Date:  2013-06       Impact factor: 8.086

Review 5.  Plasmodium cellular effector mechanisms and the hepatic microenvironment.

Authors:  Ute Frevert; Urszula Krzych
Journal:  Front Microbiol       Date:  2015-05-27       Impact factor: 5.640

6.  Silencing of HLA class I on primary human hepatocytes as a novel strategy for reduction in alloreactivity.

Authors:  Constança Figueiredo; Felix Oldhafer; Eva-Maria Wittauer; Marco Carvalho-Oliveira; Ali Akhdar; Oliver Beetz; Chen Chen-Wacker; Yuliia Yuzefovych; Christine S Falk; Rainer Blasczyk; Florian W R Vondran
Journal:  J Cell Mol Med       Date:  2019-06-10       Impact factor: 5.310

Review 7.  Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects.

Authors:  Hong Lei; Petra Reinke; Hans-Dieter Volk; Yi Lv; Rongqian Wu
Journal:  Front Immunol       Date:  2019-11-19       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.